Purification of pertussis antigens
AssigneePublic Health Laboratory Service Board
InventorsAndrew Robinson, Laurence I. Irons
Life of this patent
Estimating the term…
Abstract
A process is provided for the production of lymphocytosis promoting factor (LPF), filamentous haemagglutinin (FHA) and at least one fimbrial agglutinogen from a liquid culture of Bordetella pertussis, which comprises the steps of (a) separating the culture into cellular and supernatant fractions, (b) concentrating the supernatant fraction, (c) fractionating the concentrated supernatant fraction to isolate LPF and FHA containing fractions, and (d) isolating at least one fimbrial agglutinogen from the cellular fraction. A vaccine composition may be produced by mixing so-produced LPF, FHA and fimbrial agglutinogens produced.
Claims9
A process for the co-production of lymphocytosis promoting factor (LPF), filamentous haemagglutinin (FHA) and at least one fimbrial agglutinogen from a liquid culture of Bordetella pertussis, which comprises the steps of
- (a) separating the culture into cellular and supernatant fractions,
- (b) subsequent to step (a) concentrating the supernatant fraction to less than 50% of its original volume to form a concentrated aqueous supernatant fraction of reduced water content,
- (c) subsequent to step (b), fractionating the concentrated supernatant fraction to isolate LPF and FHA containing fractions, and
- (d) isolating at least one fimbrial agglutinogen from the cellular fraction.
Dependencies are inferred from the claim text.